此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Triapine 联合化疗和放疗治疗 IB2-IVA 宫颈癌或阴道癌患者

2026年11月11日 更新者:National Cancer Institute (NCI)

口服 triapine 联合同步放化疗治疗局部晚期宫颈癌 (LACC) 和阴道癌的 I 期剂量递增生物利用度研究

This phase I trial studies the side effects and best dose of triapine when given with radiation therapy and cisplatin in treating patients with stage IB2-IVA cervical or vaginal cancer. Triapine may stop the growth of cancer cells by blocking an enzyme needed for cell growth. Cisplatin is a drug used in chemotherapy that kills cancer cells by damaging their deoxyribonucleic acid (DNA) and stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Adding triapine to standard treatment with cisplatin and radiation therapy may kill more cancer cells.

研究概览

详细说明

PRIMARY OBJECTIVES:

I. To determine the maximum tolerable dose (MTD) and recommended phase II dose (RP2D) of oral triapine when used in combination with cisplatin plus radiation therapy.

II. To determine the oral bioavailability of triapine. III. To describe the pharmacokinetics (PK) of oral and intravenous triapine.

SECONDARY OBJECTIVES:

I. To determine whether the metabolic complete response (mCR) rate of oral triapine in combination with cisplatin chemoradiation using fludeoxyglucose F 18 (18F-FDG)-positron emission tomography (PET)/computed tomography (CT) at post-therapy (3-month) is at least 70%.

II. To determine clinical overall response rate, progression-free survival, and overall survival.

III. To determine the correlation of methemoglobin proportion (%) and triapine pharmacokinetic exposure.

EXPLORATORY OBJECTIVE:

I. To determine whether active human immunodeficiency virus (HIV) antiretroviral therapy impacts the antitumor activity of triapine.

OUTLINE: This is a dose-escalation study of triapine.

Patients undergo pelvic external beam radiation therapy (EBRT) or intensity modulated radiation therapy (IMRT) 5 days per week for 5 weeks (25 fractions) with a 3-day boost in week 6, and 1 or 2 applications of low dose rate (LDR) brachytherapy in week 6 or 5 fractions of high dose rate (HDR) brachytherapy at week 4 or 5. Patients also receive triapine intravenously (IV) over 120 minutes on day 1 and orally (PO) on days 2-5, 8-12, 15-19, 22-26, and 29-33 within 90 minutes after pelvic irradiation, and cisplatin IV over 60-120 minutes once weekly for 5 weeks (days 2, 9, 16, 23, and 30). Treatment continues in the absence of disease progression or unacceptable toxicity. Patients may receive a 6th cycle of cisplatin IV during the parametrial boost or any make-up radiation treatment in a sixth week of external beam radiotherapy. Patients undergo the collection of blood samples on study and undergo magnetic resonance imaging (MRI) and FDG-PET/CT during follow-up.

研究类型

介入性

注册 (实际的)

21

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Alabama
      • Birmingham、Alabama、美国、35233
        • University of Alabama at Birmingham Cancer Center
    • California
      • Los Angeles、California、美国、90033
        • USC / Norris Comprehensive Cancer Center
      • Los Angeles、California、美国、90033
        • Los Angeles General Medical Center
      • Pasadena、California、美国、91105
        • Keck Medical Center of USC Pasadena
    • Kansas
      • Fairway、Kansas、美国、66205
        • University of Kansas Clinical Research Center
      • Kansas City、Kansas、美国、66160
        • University of Kansas Cancer Center
      • Overland Park、Kansas、美国、66211
        • University of Kansas Hospital-Indian Creek Campus
      • Westwood、Kansas、美国、66205
        • University of Kansas Hospital-Westwood Cancer Center
    • Kentucky
      • Lexington、Kentucky、美国、40536
        • University of Kentucky/Markey Cancer Center
    • Michigan
      • Ann Arbor、Michigan、美国、48109
        • University of Michigan Rogel Cancer Center
      • Detroit、Michigan、美国、48201
        • Wayne State University/Karmanos Cancer Institute
      • Farmington Hills、Michigan、美国、48334
        • Weisberg Cancer Treatment Center
    • New Jersey
      • New Brunswick、New Jersey、美国、08903
        • Rutgers Cancer Institute of New Jersey
    • Oklahoma
      • Oklahoma City、Oklahoma、美国、73104
        • University of Oklahoma Health Sciences Center
    • Pennsylvania
      • Pittsburgh、Pennsylvania、美国、15232
        • UPMC Hillman Cancer Center
    • Virginia
      • Charlottesville、Virginia、美国、22908
        • University of Virginia Cancer Center
      • Richmond、Virginia、美国、23298
        • VCU Massey Comprehensive Cancer Center

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

女性

描述

Inclusion Criteria:

  • Patient has a new, untreated histologic diagnosis of stage IB2 (> 5 cm), II, IIIB, IIIC or IVA squamous, adenocarcinoma, or adenosquamous carcinoma of the uterine cervix or stage II-IVA squamous, adenocarcinoma, or adenosquamous carcinoma of the vagina not amenable to curative surgical resection alone; the presence or absence of lymph node metastasis will be based on pre-therapy 18F-FDG PET/CT; the patient must be able to tolerate imaging requirements of an 18F-FDG PET/CT scan

  • Age >= 18 years old

  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2

  • Life expectancy greater than 6 months

  • Absolute neutrophil count (ANC) >= 1.5 x 10^9/L

  • Platelets >= 100 x 10^9/L

  • Hemoglobin (Hgb) >= 10.0 g/dL (blood transfusions to reach this amount are allowed)

  • Serum creatinine =< 1.5 mg/dL to receive weekly cisplatin

    • If serum creatinine is between 1.5 and 1.9 mg/dL, patients are eligible for cisplatin if the estimated creatinine clearance (CCr) is > 30 ml/min (for the purpose of estimating the CCr, the formula of Cockcroft and Gault for females should be used)
  • Total serum bilirubin =< 1.5 x upper limit of normal (ULN) (in patients with known Gilbert syndrome, a total bilirubin =< 3.0 x ULN, with direct bilirubin =< 1.5 x ULN)

  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN

  • Able to take oral medication

  • Not pregnant and not breastfeeding; the effects of triapine on the developing human fetus are unknown; for this reason as well as because heterocyclic carboxaldehydethiosemicarbazones and radiation are known to be teratogenic, women of child-bearing potential and men must agree to use two forms of contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; patient must have documented negative urine pregnancy test must be resulted within 7 days before initiating protocol therapy; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with triapine, breastfeeding should be discontinued if the mother is treated with triapine; these potential risks may also apply to other agents used in this study

  • For HIV and hepatitis B/C (HEPB/C):

    • HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for the dose escalation portion of this trial; for those patients who are enrolled in the HIV positive (+) expansion cohort, they must be HIV infected and be on retroviral therapy with an undetectable viral load within 6 months of enrollment
    • For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
    • Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured; for patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
  • Able to understand and willingness to sign a written informed consent document

Exclusion Criteria:

  • Patient has had a prior invasive malignancy diagnosed within the last three years (except [1] non-melanoma skin cancer or [2] prior in situ carcinoma of the cervix)
  • Patients are excluded if they have received prior pelvic radiotherapy for any reason that would contribute radiation dose that would exceed tolerance of normal tissues at the discretion of the treating physician
  • Patients receiving any other investigational agents
  • Patients with known glucose-6-phosphate dehydrogenase deficiency (G6PD) are excluded due to an inability to administer the antidote for methemoglobinemia, methylene blue; pre-registration testing for G6PD is at the investigator's discretion and is not required for study enrollment
  • Patients who are taking any medication associated with methemoglobinemia; medication must be discontinued and must have a washout period of 4 halflives or 4 weeks, whichever is shorter
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to triapine or cisplatin
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection; symptomatic congestive heart failure; unstable angina pectoris; cardiac arrhythmia; known inadequately controlled hypertension; significant pulmonary disease including dyspnea at rest, patients requiring supplemental oxygen, or poor pulmonary reserve; or psychiatric illness/social situations that would limit compliance with study requirements
  • Patients with uncontrolled diabetes mellitus (fasting blood glucose controlled by medication, =< 200 mg/dL allowed)
  • Patients who have had a hysterectomy or are planning to have an adjuvant hysterectomy following radiation as part of their cervical cancer treatment are ineligible
  • Patients scheduled to be treated with adjuvant consolidation chemotherapy at the conclusion of their standard chemoradiation

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Treatment (triapine, chemoradiation)

Patients undergo pelvic EBRT or IMRT 5 days per week for 5 weeks (25 fractions) with a 3-day boost in week 6, and 1 or 2 applications of LDR brachytherapy in week 6 or 5 fractions of HDR brachytherapy at week 4 or 5. Patients also receive triapine IV over 120 minutes on day 1 and PO on days 2-5, 8-12, 15-19, 22-26, and 29-33 within 90 minutes after pelvic irradiation, and cisplatin IV over 60-120 minutes once weekly for 5 weeks (days 2, 9, 16, 23, and 30). Treatment continues in the absence of disease progression or unacceptable toxicity. Patients may receive a 6th cycle of cisplatin IV during the parametrial boost or any make-up radiation treatment in a sixth week of external beam radiotherapy. Patients undergo the collection of blood samples on study and undergo MRI and FDG-PET/CT during follow-up.

Given IV

其他名称:
  • CDDP
  • 顺式二氨合二氯铂
  • 顺铂
  • 新铂
  • 铂醇
  • 阿比铂
  • Blastolem
  • 布铂
  • 顺式二氨二氯铂
  • 顺式二氨二氯铂 (II)
  • 顺式二氯胺铂 (II)
  • 顺铂二氯化胺
  • 顺铂II
  • 顺铂II二胺二氯化物
  • 胞铂
  • 胞磷胆素
  • 扁豆属
  • 民进党
  • 莱德铂
  • 金属铂
  • 佩龙氯化物
  • 佩龙盐
  • 普拉西斯
  • 塑化剂
  • 铂金
  • 铂菌素
  • Platiblastin-S
  • 铂金-AQ
  • Platinol-AQ VHA Plus
  • 铂氧生
  • 铂
  • 二氯化铂
  • 普拉蒂兰
  • 普拉汀
  • 柏拉图素

Undergo MRI

其他名称:
  • 核磁共振
  • 磁共振
  • 磁共振成像扫描
  • 医学影像、磁共振/核磁共振
  • 先生
  • 磁共振成像
  • 核磁共振成像扫描
  • 核磁共振成像
  • 磁共振成像 (MRI)
  • 磁共振成像(程序)
  • 结构核磁共振

Correlative studies

Undergo collection of blood samples

其他名称:
  • 生物样本采集
  • 收集的生物样本
  • 标本采集
  • 样本收集

Undergo IMRT

其他名称:
  • 调强放射治疗
  • 调强放疗
  • 辐射、调强放射治疗
  • 调强放射治疗(程序)

Undergo FDG-PET/CT

其他名称:
  • CT
  • 猫
  • 电脑扫描
  • 计算机轴向断层扫描
  • 计算机断层扫描
  • CT扫描
  • 断层扫描
  • 计算机轴向断层扫描(程序)
  • 计算机断层扫描 (CT) 扫描
  • 诊断猫扫描
  • 诊断猫扫描服务类型

Undergo FDG-PET/CT

其他名称:
  • 医学成像、正电子发射断层扫描
  • 宠物
  • 宠物扫描
  • 正电子发射断层扫描
  • PT
  • 正电子发射断层扫描(程序)

Undergo LDR brachytherapy

其他名称:
  • 近距离放射治疗,NOS
  • 内辐射
  • 内照射近距离放射治疗
  • 内部放射治疗
  • 放射近距离放射治疗
  • 辐射,内部

Undergo pelvic EBRT

其他名称:
  • EBRT
  • 根治性放射治疗
  • 外部光束辐射
  • 外照射放射治疗
  • 外照射放疗
  • 外部辐射
  • 外放射治疗
  • 外光束辐射
  • 辐射,外光束
  • 远程放射治疗
  • 远程治疗
  • 远距离放射治疗
  • 外照射放射治疗(常规)

Undergo FDG-PET/CT

其他名称:
  • 18FDG
  • 葡萄糖
  • 氟脱氧葡萄糖 F 18
  • 氟脱氧葡萄糖 (18F)
  • 氟脱氧葡萄糖F18
  • Fluorine-18 2-Fluoro-2-deoxy-D-Glucose

Undergo HDR brachytherapy

其他名称:
  • 近距离放射治疗,高剂量
  • 高动态范围
  • 高剂量近距离放射治疗(程序)

Given IV and PO

其他名称:
  • 3-氨基吡啶-2-甲醛缩氨基硫脲
  • 3-AP
  • 3-Apct
  • OCX-0191
  • OCX-191
  • OCX191
  • PAN-811

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
消除半衰期 (t 1/2)
大体时间:给药后 24 小时内
给药后 24 小时内
Maximum Tolerated Dose (MTD)
大体时间:Up to 5 weeks

The MTD was determined following a standard 3+3 design is as follows: Escalation at 0/3 DLTs, dose-reduction if >1/3 DLT, and expansion to 6 if 1/3 DLTs. DLT is defined as the severe toxicity event that leads to the termination of the treatment as defined in section 5.5. The highest dose level where <2/6 DLTs are observed will be declared MTD

Up to 5 weeks
Number of Patients Who Experienced a DLT
大体时间:Up to 5 weeks

Number of patients that experienced a DLT, evaluated using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0. DLTs are defined as the following adverse events if considered at least "possibly related" to a component of the study therapy and which occur from the start of treatment until completion of EBRT, prior to initiation of brachytherapy (i.e. the first 5 weeks if no treatments are missed): Any nausea, vomiting, diarrhea and elevation of serum creatinine level Grade 3 toxicity not resolved with maximal intervention to Grade 0-2 over 7 days (except alopecia and fatigue); Any nausea, vomiting, diarrhea and elevation of serum creatinine level Grade 4 toxicity; Any other non-hematologic toxicity ≥Grade 3; Any hematologic toxicity of ≥ Grade 4; Grade ≥3 dyspnea; Inability to deliver at least 20 of the scheduled 25 administrations of triapine at the planned dose, allowing for 2 weeks to make up missed radiation days.

Inability to deliver

Up to 5 weeks
Bioavailability of Triapine
大体时间:Up to 2 weeks

The oral bioavailability of the oral form of the triapine will be measured as a numeric value using mass spectrophotometry.

Up to 2 weeks
Cmax
大体时间:Up to 24 hours after dosing

Maximum concentration

Up to 24 hours after dosing
Tmax
大体时间:Up to 24 hours after dosing

Time to maximum concentration,

Up to 24 hours after dosing
AUC
大体时间:Up to 24 hours after dosing

Area Under the Concentration-Time Curve (AUC 0-last)

Up to 24 hours after dosing

次要结果测量

结果测量
措施说明
大体时间
Fludeoxyglucose F18-Positron Emission Tomography Computed Tomography Metabolic Complete Response (mCR) Rate
大体时间:At 3 months post-treatment

The mCR rate at recommended phase 2 dose, defined as a metabolic complete response on PET/CT will be defined as greater than -66% reduction in tumor FDG uptake at sites of abnormal tumor FDG uptake noted on pre-treatment FDG-PET study (considering normal cardiac or liver blood pool).

At 3 months post-treatment
Clinical Overall Response Rate
大体时间:3 months post-treatment

Clinical response at the recommended phase 2 dose per RECIST v1.1 Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression). Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

3 months post-treatment
Progression Free Survival (PFS)
大体时间:Up to 4 years and 2 months from start of treatment

Median number of months that patients survive without disease progression from end of treatment. Per RECIST v1.1, Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).

Up to 4 years and 2 months from start of treatment
Overall Survival (OS)
大体时间:Up to 4 years and 2 months from start of treatment

Median number of months that patients remain alive after end of treatment.

Up to 4 years and 2 months from start of treatment

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Sarah E Taylor、University of Pittsburgh Cancer Institute LAO

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2019年9月18日

初级完成 (实际的)

2023年6月4日

研究完成 (估计的)

2027年4月29日

研究注册日期

首次提交

2015年11月3日

首先提交符合 QC 标准的

2015年11月3日

首次发布 (估计的)

2015年11月4日

研究记录更新

最后更新发布 (实际的)

2026年11月13日

上次提交的符合 QC 标准的更新

2026年11月11日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅